Cell Therapeutics, Inc. (NASDAQ:CTIC)

CAPS Rating: 2 out of 5

The Company develops, acquires and commercializes novel treatments for cancer and focuses its research and in-licensing activities on identifying and developing new, less toxic and effective ways to treat cancer.

Recs

0
Player Avatar hldhstg (< 20) Submitted: 6/4/2009 9:24:30 PM : Outperform Start Price: $10.50 CTIC Score: -131.08

Sixth Sense?

Featured Broker Partners


Advertisement